A new therapy to treat and prevent arthritis in joints
Official title: Treatment and prevention of osteoarthritis with an intra-articular disease-modifying regenerative therapy
Funded at Regenosine INC · NIH-11170762 · Data updated 2026-11-12
This project is developing a new injection to help repair joint cartilage and stop osteoarthritis from getting worse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Regenosine INC NIH-funded |
| Lab location | 1 site (Princeton, UNITED STATES) |
| Project start | August 5, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $399,378 |
| NIH project number | 5SB1AR084381-02 |
| Project ID | NIH-11170762 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with established osteoarthritis who are looking for alternatives to surgery or current symptomatic treatments might be ideal candidates for future studies.
✕Less likely to help
Patients without osteoarthritis or those seeking immediate pain relief without addressing cartilage regeneration may not directly benefit from this specific therapy.
What this research studies
Osteoarthritis is a common joint disorder that currently lacks therapies to prevent its progression or reverse cartilage loss, often leading to joint replacement surgery. This project is developing a first-in-class injection called Regenosine, which uses a special formulation of adenosine to regenerate cartilage. The goal is to offer patients a novel, disease-modifying therapy that significantly improves clinical outcomes and quality of life. Early tests in animal models have shown that this intra-articular injection can reverse and reduce the severity of osteoarthritis.
Why it matters
Potential benefit: If successful, this therapy could offer patients a way to regenerate damaged cartilage, slow down or reverse osteoarthritis progression, and potentially avoid joint replacement surgery.
How similar studies have gone: While current therapies for osteoarthritis do not regenerate cartilage, this novel approach has shown promising results in animal models, suggesting a new direction for treatment.
Where this research is happening
-
Regenosine INC
Princeton, United States Active
Researchers
- Principal investigator: Angle, Siddhesh — Regenosine INC
- Study coordinator: Angle, Siddhesh
Related research
Other NIH-funded projects on the same topics.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Digital biomarkers to guide personalized rehab after ACL injury
Aims to use wearable sensors and phone videos to predict early osteoarthritis risk after ACL surgery so rehabilitation can be tailored to each patient.
-
Aberrant mechano-oxygen coupling linked to zinc-rich mineralization in osteoarthritis
Aims to understand how abnormal joint forces affect cartilage and bone, causing zinc-rich mineral deposits and harmful blood vessel growth in osteoarthritis.
-
Notch signaling in TMJ osteoarthritis: uncovering mechanisms and new targets
Researchers are studying how Notch signaling affects TMJ osteoarthritis to identify new ways to protect and repair the jaw joint.
-
Nanoparticles delivering an sPLA2 blocker for knee osteoarthritis
This project uses tiny, drug-filled nanoparticles to deliver an sPLA2-blocking medicine into the knee to reduce inflammation and slow knee osteoarthritis in people with painful knee OA.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.